RxDoctor Payments Data

Richard Moody, MD

Family Medicine · Chattanooga, TNNPI 1457325862

Payments from drug & device makers

$10,480in general payments, 2019–2025

Across 688 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Lilly USA, LLC$1K
  • AstraZeneca$878
  • Pfizer$758
  • Amarin Pharma, Inc.$520
  • Amgen$462
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$10,448100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,480 in reported general payments places this provider in the 90th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$253,860
Medicare patients
636
Services billed
6,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide92$159,270
JardianceEmpagliflozin110$119,117
OzempicSemaglutide55$84,526
FarxigaDapagliflozin Propanediol82$80,522
JanuviaSitagliptin Phosphate77$61,711
EliquisApixaban60$60,881
Tresiba Flextouch U-200Insulin Degludec49$36,801
Soliqua 100-33Insulin Glargine/Lixisenatide29$35,742
TrulicityDulaglutide18$28,805
Xultophy 100-3.6Insulin Degludec/Liraglutide17$20,955
XareltoRivaroxaban22$18,785
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog39$17,486
Tresiba Flextouch U-100Insulin Degludec20$14,440
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$12,618
LinzessLinaclotide12$11,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic, Xultophy 100-3.6$2,636$264,751164 claims
Boehringer IngelheimJardiance$422$119,117110 claims
AstraZenecaFarxiga$878$80,52282 claims
MerckJanuvia$270$61,71177 claims
PfizerEliquis$758$60,88160 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$343$35,74229 claims
Lilly USA, LLCTrulicity$1,050$28,80518 claims
Johnson & JohnsonXarelto$424$18,78522 claims
AbbVieLinzess, Synthroid$156$13,55534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →